Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Kathy Steece-CollierJennifer A StancatiNicholas J CollierIvette M SandovalNatosha M MercadoCaryl E SortwellTimothy J CollierFredric P ManfredssonPublished in: Movement disorders : official journal of the Movement Disorder Society (2019)
The current data provide some of the most profound antidyskinetic benefit reported to date and suggest that genetic silencing of striatal CaV1.3 channels has the potential to transform treatment of individuals with PD by allowing maintenance of motor benefit of levodopa in the absence of the debilitating levodopa-induced dyskinesia side effect. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.